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Chronic bee paralysis virus (CBPV) causes an infectious and contagious disease of adult honeybees. Its segmented genome is
composed of two major positive single-stranded RNAs, RNA 1 (3,674 nt) and RNA 2 (2,305 nt). Three minor RNAs (about 1,000 nt
each) have been described earlier but they were not detected by sequencing of CBPV genome. In this study, the results of in vivo
inoculation of the two purified CBPVmajor RNAs are presented and demonstrate that RNA 1 and RNA 2 are infectious. Honeybees
inoculated with 109 RNA copies per bee developed paralysis symptoms within 6 days after inoculation.The number of CBPV RNA
copies increased significantly throughout the infection. Moreover, the negative strand of CBPV RNA was detected by RT-PCR,
and CBPV particles were visualized by electronic microscopy in inoculated honeybees. Taken together, these results show that
CBPV RNA 1 and CBPV RNA 2 segments can induce virus replication and produce CBPV virus particles. Therefore, the three
minor RNAs described in early studies are not essential for virus replication.These data are crucial for the development of a reverse
genetic system for CBPV.
1. Introduction
Honeybee (Apis mellifera) is one of the most important pol-
linators with a big impact on agriculture and economics [1].
Honeybee is susceptible to a wide variety of environmental
threats (climate, urbanization, predators, pesticides,. . .) and
diseases. The chronic bee paralysis virus (CBPV) is responsi-
ble for a contagious and infectious disease of adult honeybee
that can lead tomortalities, the chronic paralysis disease.This
pathology is characterized by clusters of trembling, flightless,
crawling bees, and individual black, hairless bees standing at
the hive entrance [2].
CBPV can be transmitted by two main routes: (i) contact
between infected and noninfected bees [3] and (ii) spread
of infectious particles in the feces of paralyzed bees that
are taken up orally by healthy nest mates [4]. CBPV, first
isolated in 1963 [2], has anisometric particles that measure
30–60 nm in length and 20 nm in width [5]. It is a positive
single-stranded RNA virus and its genome is composed of
two major RNAs, RNA 1 (3,674 nucleotides [nt]) and RNA
2 (2,305 nt) [6].The genomic RNAs are not polyadenylated at
their 3󸀠-end and have a CAP structure at the 5󸀠-end. RNA 1
and RNA 2 encode three and four overlapping Open Reading
Frames (ORFs), respectively. RNA 1-ORF3 is predicted to
encode the RNA-dependent RNA polymerase (RdRp) [6].
RNA 2-ORF2 and RNA 2-ORF3 are thought to encode two
structural proteins (hSP and pSP, resp.) [7]. To date, CBPV
remains unclassified by the International Committee on
Taxonomy of Viruses (ICTV) (http://www.ictvonline.org/).
Only RNA 1-ORF3 shows similarities with Nodaviridae and
Tombusviridae family [6]. Runckel et al. [8] discovered new
viral sequences (Lake Sinai 1 virus and Lake Sinai 2 virus)
highly related to CBPV which might belong to the same
viral family. Moreover, Schuster et al. [9] described a new
virus named mosinovirus related to LSV and to CBPV. The
authors suggested that these viruses could belong to a new
viral family.
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In addition to the two major RNAs, three minor RNAs
have been described in the early studies of CBPV [10]. How-
ever, these minor RNAs were not reported in any subsequent
study. They were not visualized on gel and were not detected
by sequencing [6]. Recently, it has been shown that total
RNA obtained from purified CBPV particles is infectious
after direct inoculation in honeybee [11]. However, since total
RNA preparation can contain both major and minor RNAs,
it was not possible to conclude about the possible role of
the minor RNAs. Besides, the determination of the genetic
elements essential to recover an infectious virus is needed in
order to establish a reverse genetic system for CBPV.
In this study, our goal was to determine whether CBPV
RNA 1 and CBPV RNA 2 inoculated together were sufficient
to induce the virus replication and the chronic paralysis
disease. After purification of the two major RNAs by gel elec-
trophoresis, emerging bees were inoculated with 109 RNAs
copies per bee. The infectivity of CBPV major RNAs was
demonstrated by observation of the clinical signs of CBPV
infection, quantification of the viral genome by RT-qPCR
throughout infection, detection of the antigenomic strand
of CBPV RNA, and observation of CBPV viral particles by
electron microscopy.
2. Materials and Methods
2.1. Maintenance of Honey Bee Colonies. This study was
performed in January 2015. The queens were changed six
months before the experiment and the new colonies were
placed in new hives equipped with new frames. In October
2014, these hives were placed in a room heated to 32∘C and
were supplied by sucrose syrup complemented with protein
L (Calier Laboratory, Spain).The absence of CBPV and other
bee viruses was checked regularly by RT-PCR.
2.2. Virus Purification. Five- to seven-day-old honeybees
(450 emerging bees) collected from CBPV-free colonies were
used to produce CBPV by injection of the A79-P isolate
(NC 010712.1). After observation of chronic paralysis signs
(5 to 6 days after inoculation), CBPV particles were purified
from the heads of bees by ultracentrifugation on a 10 to 40%
(w/v) sucrose gradient as previously described by Olivier et
al. [6].
2.3. CBPV Major RNAs Purification. The genomic RNAs
(naked RNAs) were extracted from the purified A79-P isolate
using the High Pure Viral RNA Kit (Roche) and recovered in
50𝜇L of RNAse-free water. Extracted RNA was denatured by
heating at 70∘C and chilled for 5min at 4∘C and submitted
to electrophoresis on a 1% low melting agarose gel using
MOPS/formaldehyde buffer during 4.5 h. The RNA 1 and
RNA 2 fragments were cut from the gel and extracted using
QIAquick Gel Extraction Kit (Qiagen).
2.4. Experimental Inoculation: Sample Preparation and Collec-
tion. Emerging honeybees were collected from a CBPV-free
colony. They were maintained for 5 to 7 days at 32∘C in small
cages providing ad libitum sugar candy and sucrose syrup
complemented with protein L (Calier Laboratory, Spain).
Eight bees from each cage were collected before the inocu-
lation as negative controls. The remaining bees were anaes-
thetized with carbon dioxide (CO
2
) and inoculated with 4 𝜇L
of phosphate buffer (PB, pH 7) suspension containing whole
CBPV particles (A79-P isolate), naked RNA, or major RNA
mixture via intrathoracic injection (Table 1). Immediately
after inoculation, 8 bees from each experimental condition
were sampled to quantify the RNA loads. The bees were
then incubated at 32∘C for 6 days and the clinical signs were
observed and recorded daily. Asymptomatic, symptomatic,
and dead bees were recovered daily and stored separately at
−80∘C.
2.5. RNA Extraction and cDNA Synthesis. Bees were individ-
ually crushed in 1mL of 0.01mM PB. After two clarifications
of the homogenate by centrifugation (10min at 8,000×g), the
viral RNA was extracted using the High Pure Viral RNA Kit
(Roche) according to the manufacturer’s recommendations.
The quantity and quality of purified RNA were estimated by
measuring the optical density at 260 nm and 280 nm. Com-
plementary DNA was synthesized by reverse transcription as
described by Ribie`re et al. [12].
2.6. CBPV Major RNA Quantification by Real-Time Reverse-
Transcription PCR (RT-qPCR). The RNA 1 fragment was
quantified by RT-qPCR as described by Blanchard et al.
[13]. A new RT-qPCR was set up for RNA 2 quantification.
CBPV RNA 2 sequences available in GenBank were aligned,
and primers and probes were designed using the Primer
Express software (Applied Biosystems) in the conserved
region. Because no consensus sequences were found, several
sequences were selected for each primer and the probe. The
selected primers amplify a fragment (72 to 74 nt long) and
are located in the coding region of the predicted structural
protein pSP (RNA 2, ORF3). The forward, reverse primers
and TaqMan probes are detailed in Table 2. The probes
were labeled with the fluorescent reporter dye FAM (6-
carboxyfluorescein) at the 5󸀠-end and with the fluorescent
quencher dye TAMRA at the 3󸀠-end.
The number of RNA copies was estimated using 5 𝜇L
cDNA by RT-qPCR carried out on a 7500 Real-Time PCR
system (Applied Biosystems, USA). Briefly, the PCR reaction
was performed in duplicate in a MicroAmp Optical 96-
Well Plate, containing 1X TaqMan Universal PCR Master
Mix with uracil-N-glycosylase (UNG) (Applied Biosystems,
USA), 320 nM of each primer mix (forward and reverse
primer mix), 200 nM of the qCBPV probe mix, 1X Exo
Internal Positive Control (IPC) Mix VIC (Applied Biosys-
tems, USA), 1X Exo IPC DNA (Applied Biosystems, USA),
and 5 𝜇L of standard template (108 to 102 DNA copies of
pGEM-T Easy [Promega] recombinant plasmid containing
the pSP sequence) or cDNAs in a total volume of 25 𝜇L. The
thermal cycling conditions were 2min at 50∘C (active tem-
perature for UNG to degrade any carryover DNA amplified
from previous reactions) and 10min at 95∘C (activation of
AmpliTaq Gold DNA Polymerase and degradation of UNG),
followed by 40 cycles of denaturation at 95∘C for 15 s and
annealing/extension at 60∘C for 1min.
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Table 1: Experimental conditions and bee sampling.
Conditions CBPVRNA copy number per bee Number of bees per cage
Bees not inoculated (negative control: NC) 0 30
Bees inoculated with inoculation buffer (IB) 0 30
Bees inoculated with CBPV particles (VP) 4.0 × 104 40
Bees inoculated with CBPV (naked RNAs) 4.0 × 109 65
Bees inoculated with the mix of CBPV RNA 1 + RNA 2 (major RNAs) 4.0 × 109 65
Table 2: Sequences of the primers and probes used for the CBPVRNA2RT-qPCR.Oligonucleotide sequences are located onRNA2 complete
genome of the A-79P isolate (NC 010712.1).
Equimolar mixture Sequences Position on CBPV-RNA 2(based on A79-P isolate)
Forward primer mix AGGCGCCGTAGCTGTTTCT 590–608 nt
1
GCGCCGTGGCTGTTTCT 592–608 nt
Reverse primer mix
CCCCGATCATATAAGCAAACTTCTC 637–663 nt
CCCGATCATATAGGCAAACTTCTC 639–662 nt
CCCCGATCATATATGCAAACTTCTC 639–663 nt
Probe mix CTGCGGTACTCAGCTCAGCTCGACG 610–634 nt
TGCGGTACTCAGCTCAGCTCGGC 611–631 nt
1nt: nucleotide.
2.7. Detection of Bee Viruses. Before the inoculation, a mul-
tiplex RT-PCR [14] was performed to verify the absence
of other bee viruses using previously published primers:
black queen cell virus (BQCV) [15], acute bee paralysis virus
(ABPV) [16], deforming wing virus (DWV) [17], Israeli acute
bee paralysis virus (IAPV) [18], and sacbrood virus (SBV)
[19]. In addition, bees were tested for Lake Sinai virus by RT-
PCR according to Runckel et al. [8].
2.8. Detection of CBPV Negative RNA. To assess the CBPV
replication, we used a specific RT-PCR to detect the negative
strand form of CBPV RNA as developed by Celle et al. [20].
2.9. Transmission ElectronMicroscopy. The formation of viral
particles was checked using electron microscopy. All RNA
samples of bees inoculated with CBPV major RNAs showing
a load of>1010 RNAs copies per𝜇Lweremixed together. After
addition of 2.5mL carbon tetrachloride (CCl4), homogenates
were incubated for 1 h at 4∘C and then clarified at 200×g
for 10min at 4∘C. Aqueous phases were recovered and
centrifuged at 1,700×g for 1 h at 4∘C. Ultracentrifugation of
supernatants was carried out at 75,000×g for 3.5 h at 4∘C.
The pellet was resuspended in 50𝜇L PB. All the samples were
diluted with water to 0.1mg/mL, the negative control was
dilutedwith the same 1/25 ratio, and 3.5𝜇Ldropswere applied
onto glow-discharged formvar-carbon coated grids (Agar
Scientific). After 1min incubation at room temperature, the
liquid excess was blotted off and the grids were rinsed with
water before being stained with uranyl acetate 1%. Grids were
transferred into a FEI Tecnai Spirit G2 Electron Microscope
operated at 120 kV and imaged with an EAGLE 2kX2k CCD
camera at a nominal magnification of 18,000x and with an
underfocus of approximately 2.5 𝜇m.
3. Results
3.1. CBPV Major RNA Purification. The total RNA extracted
from the purified CBPV particles (A79-P isolate) was run
on a MOPS/formaldehyde gel to separate RNA 1 and RNA
2 (Figure 1). After the electrophoresis, only major RNAs
were visualized. No fragment of about 1,100 base long was
visualized.The fragments of RNA 1 and RNA 2 were cut from
the gel and purified, and their amountswere calculated byRT-
qPCR. The quantity estimated of purified RNA 1 was about
2.1 × 1010 copies per 𝜇L and purified RNA 2 was about 8.3 ×
1010 copies per 𝜇L. Each RNA was diluted to 1.0 × 109 RNAs
copies per 𝜇L. Then, RNA 1 and RNA 2 were mixed together
(major CBPV RNAs) to be inoculated to the bees.
3.2. Validation of the CBPV RNA 2 RT-qPCR. In order to
evaluate the CBPV RNA 2 RT-qPCR, four independent runs
were performed using a 10-fold serial dilution of a plasmid
DNA control as standard. The standard curve (Figure 2)
showed a linear correlation between Ct and log
10
DNA
concentration of each run (𝑅2 = 0.998).The slope of theDNA
standard curve was −3.27 and the average efficiency of RNA 2
RT-qPCR was 102%.The limit of quantification was 100 DNA
copies per reaction.
3.3. Symptoms of Chronic Bee Paralysis. Bees were exposed
to five different treatment groups including (i) bees not
inoculated, (ii) bees inoculated with PB, (iii) bees inoculated
with CBPV particles, (iv) bees inoculated with CBPV naked
RNAs, and (v) bees inoculated with CBPV major RNAs
(Table 1). CBPV clinical signs were observed and dead bees
were collected daily. Figure 3 shows the cumulative percent-
ages of dead, symptomatic, or asymptomatic bees observed
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Figure 1: Gel electrophoresis separation of RNA 1 and RNA 2 seg-
ments of CBPV genome (A79-P isolate). 1X MOPS/formaldehyde
1% agarose gel. M: millennium RNA marker (Ambion).
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Figure 2: DNA standard curve of CBPV RNA 2 RT-qPCR obtained
with a 10-fold serial dilution (108 to 102 DNA copies per reaction)
of 2,710 kb plasmid including the coding sequence of the predicted
structural protein pSP on RNA 2-ORF3. Four independent runs
were performed and allowed to obtain the linear regression analysis
of the Ct measured for each amplification (𝑦-axis) versus log
10
of
DNA concentration of each dilution (𝑥-axis). The equation of the
linear regression and the correlation coefficient (𝑅2) are indicated.
in each experimental condition after 6 days of inoculation.
Bees not inoculated (NC) and those inoculated with PB
buffer only (inoculation buffer: IB) did not show any signs
of chronic paralysis throughout the experiment. However,
28% of bees not inoculated (4 bees out of 14) and 35%
inoculated with the buffer (5 bees out of 14) were dead during
the first days of the assay (2 and 4 days post-inoculation
[dpi]).The bees inoculated with CBPV particles (VP) showed
chronic paralysis signs (trembling, crawling) within 5 and
6 dpi. About 12.5% of bees were dead at 2 and 4 dpi and
87.5% were symptomatic. In the group of bees inoculated
with naked RNAs, 69% of bees were dead 6 dpi, 19% of
bees showed chronic paralysis clinical signs, and 12% bees
were asymptomatic. In the group of bees inoculated with
CBPV major RNAs, 71.4% of bees were dead within 6 dpi,
14.2% of bees showed the chronic paralysis clinical signs, and
14.2% bees were asymptomatic. Based on a chi-squared test,
a significant difference in the number of symptomatic and
Asymptomatic
Symptomatic
Mortality
NC IB VP Naked
RNAs
Major
RNAs
Conditions
0
10
20
30
40
50
60
70
80
90
100
Cu
m
ul
at
iv
e p
er
ce
nt
ag
e
Figure 3: Cumulative percentage of dead, symptomatic, and asymp-
tomatic bees after different treatments 6 days after inoculation:
Negative control (NC), CBPV-free inoculation buffer (IB), positive
control: CBPV particles (VP), CBPV naked RNAs, and CBPVmajor
RNAs.
dead bees was found between control and inoculated bees
(𝑝 < 0.001). However, no significant difference in symptoms
andmortality was found between bees inoculated with CBPV
naked RNAs and those inoculated with CBPV major RNA
(𝑝 = 0.766). This result confirms that the clinical signs
observed could be associated with RNA inoculations (naked
RNA as well as major RNA).
In addition, two other treatments were tested: bees inocu-
lated with CBPV RNA 1 or with CBPV RNA 2. Around 12.5%
(5 bees out of 40 bees) of bees inoculated with CBPV RNA
1 and 25% (7 bees out of 40 bees) of those inoculated with
CBPV RNA 2 were dead. However, no chronic bee paralysis
symptoms were observed (data not shown).
3.4. Quantification of CBPV Major RNAs in Inoculated Bees.
The number of copies of RNA 1 and RNA 2 was estimated
using RT-qPCR methods. Figure 4 shows the RNA 1 copies
number per bee after different treatments at inoculation
day (ID) and 6 days post-inoculation (6 dpi). The negative
control (NC) and IB-treated bees remained negative for
CBPV throughout the infection, whereas the RNA copy
number increased significantly when bees were inoculated
with VP, naked RNAs, and major RNAs between ID and
6 dpi. At 6 dpi, the symptomatic and dead bees inoculated
with CBPVmajor RNAs showed a similar CBPVRNA load as
those inoculatedwithCBPVparticles andCBPVnakedRNAs
(1010–1011 RNA 1 copies/bee). In contrast, the asymptomatic
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Figure 4: CBPVRNA 1 quantification in individual inoculated bees.
NC: negative control, VP: bees inoculated with CBPV viral particles,
CBPV naked RNAs, and CBPV major RNAs. This graph shows
the results of the RT-qPCR of CBPV RNA 1. Significant differences
between inoculation day (ID) and 6 days post-inoculation (dpi) for
each condition are indicated (∗∗∗) (𝑝 value < 0.001, Mann-Whitney
test).
bees inoculatedwith naked ormajor CBPVRNAs presented a
lower amount, ranging from 107 to 108 RNA copies/bee. Bees
inoculated with CBPV RNA 1 or CBPV RNA 2 only did not
show any increase of the viral load throughout the infection
(data not shown).
The quantities of RNA 1 and RNA 2 copies per bee were
estimated using the two RT-qPCR methods (Figure 5). The
results showed that there is no significant difference between
RNA 1 and RNA 2 copy numbers in the bees.The slope of the
regression curve is 0.9919 and the intercept is 0.11.
3.5. CBPV Replicative Strand Detection by Strand-Specific RT-
PCR. The replicative RNA strand was tested by a specific
RT-PCR on several samples from each condition studied
(Figure 6). Interestingly, the CBPV antigenomic strand was
detected in the bees inoculated with CBPV particles (VP),
naked RNAs, and major RNAs (Figure 6(a)), whereas it was
not detected neither in bees not inoculated (NC) nor in bees
inoculated with the phosphate buffer (IB) (Figure 6(b)).
3.6. Assembly of CBPV Particles. Transmission electron
microscopy was used to confirm the formation of viral par-
ticles (Figure 7). Six days after inoculation, bees inoculated
with CBPV major RNAs show the presence of anisometric
viral particles (Figure 7(c)). These particles, around 50 nm in
length, are physically identical to CBPVpurified particles, the
positive control (Figure 7(b)). Moreover, to ensure that the
formation of the viral particles is due to the inoculation with
CBPV major RNAs, not inoculated bees (negative control)
were examined; no CBPV particles were found (Figure 7(a)).
3.7. Absence of Other Bee Viruses. No other bee viruses were
detected by conventional RT-PCR in the bees used for the
experiments.
4. Discussion
This study demonstrates that the RNA 1 and RNA 2 segments
of the CBPV genome are the essential genetic elements for
CBPV replication and that they are sufficient to induce the
chronic bee paralysis disease.
CBPV, a worldwide virus, infects the honeybees. The
anisometric morphology of its particles is unique among bee
viruses as most of them are picorna-like viruses with icosa-
hedral particles. CBPV genome consists of positive single-
stranded RNA segments. Overton et al. [10] reported that it is
composed of five RNA fragments: the twomajor RNAs (RNA
1 and RNA 2) and three minor RNA segments: RNA 3a, RNA
3b, and RNA 3c, each of 1,100 nucleotides long. In this study,
we did not detect the minor RNAs by gel electrophoresis
during the purification of CBPV genome (Figure 1). This
result confirms the previous conclusions from Olivier et al.
[6] who sequenced the CBPV genome and did not detect
any minor RNAs. These authors showed that CBPV RNA 1
and CBPV RNA 2 encode three and four overlapping ORFs,
respectively. The RNA polymerase synthesis is supposed to
be the result of a frame-shift mechanism between the ORF1
and ORF3 of RNA 1. Very recently, Chevin et al. [7] reported
that RNA 2might support the coding sequences of structural
proteins. Kuchibhatla et al. [21] could identify homologs
of most of CBPV protein thought to be orphans. Indeed,
they found that ORF 1 of CBPV RNA 1 is homologous
to the alphavirus methyltransferase guanylyltransferase. In
addition, they found that ORF3 of CBPV RNA 2 shares
significant similarities with a virionmembrane protein found
in various insect and plant viruses, and they suggested that
ORF2 of CBPV RNA 2 may be a virion glycoprotein.
Recently, Chevin et al. [11] showed that CBPV total RNAs
purified from infected bees induce the replication of CBPV in
the honeybees and the formation of viral particles. However,
the authors did not conclude about the genetic elements
essential to the replication of CBPV. Here, we investigated
further this point. Emerging honeybees were inoculated with
purified CBPV major RNAs at 109 RNAs copies per 𝜇L. We
also inoculated bees with a lower amount of CBPV major
RNAs in an independent experiment (104major RNAs copies
per bee) and found a significant increase of CBPV RNA
level and CBPV replication in 16% of those bees (data not
shown). However, no clinical signs were observed in this
last experiment. Therefore, the efficiency of the infectivity
depends on the amount of inoculated major RNAs.
In the current study, five different treatments were tested
(Table 1). In each one, the bees were divided into three
categories: symptomatic, asymptomatic, and dead bees. The
bees not inoculated (NC) and those inoculatedwith the buffer
showed, respectively, 28% and 35% of mortality throughout
the infection, which represents, respectively, 4 and 5 bees
out of 14 (Figure 3). In these control groups, neither CBPV
(Figure 4) nor other bee viruses were found. Thus, this
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Figure 6: Antigenomic RNA detection by specific RT-PCR. 1.2% agarose gel electrophoresis of the PCR products (amplicons). (a) Three
samples of negative control (NC) and three samples of bees inoculated with CBPV particles (VP), five samples of bees inoculated with CBPV
naked RNAs, and eight samples of bees inoculated with CBPV major RNAs. (b) Three samples of negative control (NC), four samples of
bees inoculated with inoculation buffer (IB), and one sample of bees inoculated with viral particle (VP) were tested. M: 100 bp DNA marker
(TrackIt, Invitrogen).
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Figure 7: Transmission electron microscopy of homogenates from experimented bees. (a) Negative control bees, (b) positive control bees
(inoculated with CBPV particles), and (c) bees inoculated with CBPV major RNAs.
mortality can be due to the experimental and the artificial
conditions that these bees could not stand.
Bees inoculated with major RNAs showed the signs of
chronic paralysis disease within 6 days after inoculation
and 87.5% of the bees were dead or symptomatic (Figure 3),
suggesting that CBPV major RNAs are infectious. Moreover,
CBPV genomic load increased significantly after 6 days of
inoculation with CBPV major RNAs (Figures 4 and 5), up
to approximately 1012 RNAs copies/bee in dead bees. No
other bee virus could be detected by conventional RT-PCR
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indicating that the mortality and the clinical signs were
associated with CBPV replication. The amount of CBPV
RNAs needed to induce chronic paralysis is much higher
when using major RNAs (4.0 × 109 CBPV copies per bee)
compared to that needed when using the CBPV particles
(4.0 × 104 CBPV copies per bee). This may be due to several
reasons: a lower stability of purified RNAs compared to native
RNA protected by the viral capsid, partial degradation of
RNAs during the purification process, and/or lower efficiency
of infection through RNA transfection compared to that
obtained with the virus. The infection by the native virus
particles probably occurs via interaction with a cell receptor,
which may facilitate entry into cells.
CBPV is a positive single-stranded RNA virus, so the
synthesis of antigenomic RNA (negative strand) is carried
out during viral replication [19]. The negative strand form
was detected in bees inoculated with CBPV particles, naked
RNAs, and major RNAs. In addition, anisometric parti-
cles similar to CBPV particles were observed by electron
microscopy after the infection of bees with CBPV major
RNAs. These results along with those of RT-qPCR demon-
strate that CBPV major RNAs could induce CBPV genome
replication and virus particles formation in the honeybees.
In conclusion, this study shows that CBPV RNA 1 and CBPV
RNA 2 are infectious and sufficient to induce genomic repli-
cation, virus production, and the chronic paralysis disease
in honeybee. Therefore, the three minor RNAs described
in early studies are not essential for CBPV infection and
are not part of the CBPV genome. Whether minor RNAs
were subgenomic RNAs remains to be determined. It should
be noticed that they were associated with the small virus-
like particles associated with chronic bee paralysis virus [22]
and thus may result from virus contamination by a satellite
virus. Altogether, these results are crucial to develop a reverse
genetic system in order to study the CBPV genome.
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